Vascular adhesion protein-1 and renalase in regard to diabetes in hemodialysis patients

Archives of Medical Science

Volumn 8, Issue 6, 2012, Pages 1048-1052

  Koc Zorawska, Ewa ^a   Malyszko, Jolanta ^a   Zbroch, Edyta ^a   Malyszko, Jacek ^a   Mysliwiec, Michal ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

Author keywords

Diabetes; Hemodialysis; Renalase; Vascular adhesion protein 1

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CHOLESTEROL; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FERRITIN; FIBRINOGEN; GLUCOSE; HEMOGLOBIN; OXIDOREDUCTASE; RENALASE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VASCULAR ADHESION PROTEIN 1;

ADULT; ARTICLE; BLOOD CELL COUNT; BLOOD PRESSURE REGULATION; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; FEMALE; GLUCOSE BLOOD LEVEL; HEART EJECTION FRACTION; HEMODIALYSIS; HEMODIALYSIS PATIENT; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; SYSTOLIC BLOOD PRESSURE; TRIACYLGLYCEROL BLOOD LEVEL; UREA NITROGEN BLOOD LEVEL; WEIGHT GAIN;

EID: 84873174674     PISSN: 17341922     EISSN: None     Source Type: Journal    
DOI: 10.5114/aoms.2012.32413     Document Type: Article

References (25)

1. Salmi M, Jalkanen S. A 90-kilodalton endothelial cell molecule mediating lymphocyte binding in humans. Science 1992;257:1407-9.
2. Merinen M, Irjala H, Salmi M, Jaakkola I, Hänninen A, Jalkanen S. Vascular adhesion protein-1 is involved in both acute and chronic inflammation in the mouse. Am J Pathol 2005;166:793-800. (Pubitemid 40315636)
3. Mazzone T, Chait A, Plutzky J. Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studies. Lancet 2008;371:1800-9. (Pubitemid 351697956)
4. Noda K, Nakao S, Zandi S, et al. Vascular adhesion prote in-1 regulates leukocyte transmigration rate in the retina during diabetes. Exp Eye Res 2009;89:774-81.
5. Stolen CM, Madanat R, Marti L, et al. Semicarbazide sensitive amine oxidase overexpression has dual consequences: insulin mimicry and diabetes-like com plications. FASEB J 2004;18:702-4.
6. Salmi M, Stolen C, Jousilahti P, et al. Insulin-regulated increase of soluble vascular adhesion protein-1 in diabetes. Am J Pathol 2002;161:2255-62. (Pubitemid 35434869)
7. Li HY, Wei JN, Lin MS, et al. Serum vascular adhesion protein-1 is increased in acute and chronic hyperglycemia. Clin Chim Acta 2009;404:149-53.
8. Li HY, Lin MS, Wei JN, et al. Change of serum vascular adhesion protein-1 after glucose loading correlates to carotid intima-medial thickness in non-diabetic subjects. Clin Chim Acta 2009;403:97-101.
9. Lin MS, Li HY, Wei JN, et al. Serum vascular adhesion protein-1 is higher in subjects with early stages of chronic kidney disease. Clin Biochem 2008;41:1362-7.
10. Malyszko J, Malyszko JS, Pawlak K, et al. The coagulolytic system and endothelial function in cyclosporine-treated kidney allograft recipients. Transplantation 1996;62:828-30. (Pubitemid 26332849)
11. Malyszko J. Mechanism of endothelial dysfunction in chronic kidney disease. Clin Chim Acta 2010;411:1412-20.
12. Barylski M, Małyszko J, Rysz J, Mysliwiec M, Banach M. Lipids, blood pressure, kidney - what was new in 2011? Arch Med Sci 2011;7:1055-66.
13. Li HY, Jiang YD, Chang TJ, et al. Serum vascular adhesion protein-1 predicts 10-year cardiovascular and cancer mortality in individuals with type 2 diabetes. Diabetes 2011;60:993-9.
14. Couser WG, Riella MC. World Kidney Day 2011 - Protect your kidneys, save your heart. Arch Med Sci 2011;7:1-4.
15. K/DOQI Clinical Practice Guidelines for Cardiovascular Disease in Dialysis Patients. Am J Kidney Dis 2005;45(Suppl 3):S49.
16. Xu J, Li G, Wang P, et al. Renalase is a novel, soluble monoamine oxidase that regulates cardiac function and blood pressure. J Clin Invest 2005;115:1275-80. (Pubitemid 40629046)
17. Malyszko J, Malyszko JS, Mikhailidis DP, Rysz J, Zorawski M, Banach M. Hypertension and kidney disease: is renalase a new player or an innocent bystander? J Hypertens 2012;30:457-62.
18. Zbroch E, Małyszko J, Małyszko J, et al. Renalase, kidney function and markers of endothelial dysfunction in renal transplant recipients. Pol Arch Med Wewn 2012;122:174-9.
19. Malyszko J, Koc-Zorawska E, Malyszko JS, Mysliwiec M. VAP-1, a nover molecule linked to endothelial damage and kidney function in kidney allograft recipients. The Transplant Congress, Berlin 15-19.07, 2012 abstract PO24.088.
20. Aronow WS. Editorial on management of diabetes mellitus with coronary artery disease. Arch Med Sci 2011;7:928-30.
21. Hiramoto JS, Katz R, Peralta CA, et al. Inflammation and coagulation markers and kidney function decline: The Multi-Ethnic Study of Atherosclerosis (MESA). Am J Kidney Dis 2012;60:225-32.
22. García-Vicente S, Abella A, Viguerie N, et al. The release of soluble VAP-1/SSAO by 3T3-L1 adipocytes is stimulated by isoproterenol and low concentrations of TNFalpha. J Physiol Biochem 2005;61:395-401.
23. Abella A, García-Vicente S, Viguerie N, et al. Adipocytes release a soluble form of VAP-1/SSAO by a metallo - protease-dependent process and in a regulated manner. Diabetologia 2004;47:429-38. (Pubitemid 38491239)
24. Lewandowski KC, Banach E, Bienkiewicz M, Lewinski A. Matrix metalloproteinases in type 2 diabetes and nondiabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci 2011;7:294-303.
25. Malyszko J, Malyszko JS, Rysz J, et al. Renalase, hypertension, and kidney: the discussion continues. Angiology 2012 Sep. 11 [Epub ahead of print].